REG - Arecor Therapeutics - Director Dealing

Arecor TherapeuticsAnnouncement

09/06/2021 07:05

RNS Number : 2300B
  
Arecor Therapeutics PLC
  
09 June 2021
  
 

Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
 
Director Dealing
 
Cambridge, UK, 9th June 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces the following Directors' dealings:
 
Dr Andrew Richards, Non-Executive Chairman, purchased 12,500 ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") at a price of 242.7 pence per Ordinary Share.
 
Christine Soden, Non-Executive Director, purchased 12,500 Ordinary Shares at a price of 242.7 pence per Ordinary Share.
 
Jeremy Morgan, Non-Executive Director, purchased 20,503 Ordinary Shares at a price of 242.5 pence per Ordinary Share.
 
Following the transactions, the total beneficial interest of Dr Andrew Richards is 217,168 Ordinary Shares, representing 0.78% of the total voting rights, the total beneficial interest of Christine Soden is 12,500 Ordinary Shares, representing 0.05% of the total voting rights and the total beneficial interest of Jeremy Morgan is 20,503 Ordinary Shares, representing 0.07% of the total voting rights.
 
-ENDS-
 
 
For more information, please contact:



Arecor Therapeutics plc


www.arecor.com




Dr Sarah Howell, Chief Executive Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Susan Lowther, Chief Financial Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Mo Noonan, Communications


Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com




 


 




Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)


Tel: +44 (0) 20 7886 2500
 




 


 




Consilium Strategic Communications


 




Chris Gardner, David Daley, Angela Gray


Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com



 
Notes to Editors
 
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.  Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
 
For further details please see our website, www.arecor.com
 
 
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
 



  1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Andrew Richards 




2


Reason for the notification




a)


Position/status


Non-Executive Chairman




b)


Initial notification/Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Arecor Therapeutics plc




b)


LEI


98450093D12I3A8DDD58




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument


Ordinary Shares 




b)


Identification Code


GB00BMWLM973




c)


Nature of the transaction


Purchase of shares


















d)


Price(s) and volume(s)


 242.7 pence and 12,500 Ordinary Shares




e)


Aggregated information
- Aggregated volume
- Aggregated price








f)


Date of the transaction


8 June 2021




g)


Place of the transaction


London Stock Exchange, AIM



 



  1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Christine Soden 




2


Reason for the notification




a)


Position/status


Non-Executive Director




b)


Initial notification/Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Arecor Therapeutics plc




b)


LEI


98450093D12I3A8DDD58




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument


Ordinary Shares




b)


Identification Code


GB00BMWLM973




c)


Nature of the transaction


Purchase of shares


















d)


Price(s) and volume(s)


 242.7 pence and 12,500 Ordinary Shares




e)


Aggregated information
- Aggregated volume
- Aggregated price








f)


Date of the transaction


8 June 2021




g)


Place of the transaction


London Stock Exchange, AIM



 



  1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Jeremy Morgan 




2


Reason for the notification




a)


Position/status


Non-Executive Director




b)


Initial notification/Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Arecor Therapeutics plc




b)


LEI


98450093D12I3A8DDD58




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument


Ordinary Shares




b)


Identification Code


GB00BMWLM973




c)


Nature of the transaction


Purchase of shares


















d)


Price(s) and volume(s)


 242.5 pence and 20,503 Ordinary Shares




e)


Aggregated information
- Aggregated volume
- Aggregated price








f)


Date of the transaction


8 June 2021




g)


Place of the transaction


London Stock Exchange, AIM



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHBLGDLUXGDGBI